Death and Near-Death Experiences in Ketamine and Psychedelic Therapy

This synthesis reviews evidence on near-death-like experiences during ketamine- or psychedelic-assisted therapy for cancer-related distress, treatment-resistant depression, or end-of-life existential fear. Findings indicate such experiences are recurring, with ketamine and DMT most closely reproducing spontaneous near-death phenomenology across independent methodologies. Experience intensity correlates with reduced death anxiety and depressive symptoms in psilocybin trials. Evidence quality varies: psilocybin's effect on anxiety and depression in life-threatening illness rests on low-certainty randomized evidence; its effect on existential distress rests on a single small trial; ketamine's link to reduced existential distress has not been tested in any randomized trial. A plausible neurophysiological basis for near-death phenomenology exists independently of drugs, though contested.

Study at a glance

Abstract

Patients undergoing ketamine-or psychedelic-assisted therapy for cancer-related distress, treatment-resistant depression, or end-of-life existential fear frequently report experiences resembling death or near-death: a sense of leaving the body, encountering something transcendent, or having died and returned. This synthesis reviews peer-reviewed evidence on how often this occurs, why it may occur, which drugs most closely reproduce the phenomenology of spontaneous near-death experience, and whether experience intensity tracks with clinical improvement. Evidence is drawn from randomized controlled trials, a meta-analysis, a Cochrane systematic review, large-scale survey and computational comparisons, and open-label case series, each verified directly against PubMed and Crossref records. Findings indicate that near-death-like phenomenology is a recurring rather than incidental feature of certain drug therapies; that ketamine and DMT most closely reproduce the phenomenology of spontaneous near-death experience across independent methodologies; that experience intensity correlates with reductions in death anxiety and depressive symptoms in psilocybin trials; and that a plausible neurophysiological basis for near-death phenomenology exists independent of any drug, though contested. Evidence quality varies substantially by claim: psilocybin's effect on anxiety and depression in life-threatening illness rests on low-certainty randomized evidence; its effect on existential distress specifically rests on a single small trial; and ketamine's link to reduced existential distress has not yet been tested in any randomized trial.